Head to head
Solstice Advanced Materials vs Linde
Side-by-side on the measures that matter, with a plain-English read. Full detail: SOLS · LIN
SOLS
Solstice Advanced Materials
60.55-6.21%
1-year price shape — +40% over the period
Quant Rating D · 84/100
vs
LIN
Linde
502.83-1.45%
1-year price shape — +25% over the period
Quant Rating C · 69/100
1-year performance, rebased to 100
Linde edges it on the scoreable measures. Linde pays the highest dividend yield; Linde earns the most per share.
| SOLS | LIN | |
|---|---|---|
| Snapshot | ||
| Sector | Specialty Chemicals | Specialty Chemicals |
| Last price | 60.55 | 502.83 |
| Change today | -6.21% | -1.45% |
| 1-year return | +40.4% | +24.8% |
| Market cap | $9.52B | $230.84B |
| 52-week range | 44.57 – 90.60 | 384.00 – 546.40 |
| Valuation | ||
| P/E (TTM) | 29.68 | 33.39 |
| P/E percentile, own 5-yr range | 29th | 57th |
| P/B | 6.08 | 5.86 |
| Dividend yield | 0.37% | 1.25% |
| Profitability & growth | ||
| EPS (TTM) | 1.49 | 14.61 |
| Net profit (TTM) | $234.24M | $6.71B |
| Revenue (TTM) | $4.17B | $36.24B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +7.9% | +9.2% |
| Gross margin | 30.9% | 47.9% |
| Operating margin | 17.2% | 27.1% |
| Net margin | 7.8% | 19.3% |
| Free cash flow (TTM) | $429.00M | $5.08B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 88.7% | 88.6% |
| Insider activity (12mo) | 41 buy / 9 sell | 27 buy / 16 sell |
| Short interest (% of float) | 2.9% | 1.4% |
| Analyst consensus | 86% buy / 14% hold (7) | 94% buy / 6% hold (16) |
| Analyst price target | $78 (+29%) | $570 (+13%) |
| StockVane view | ||
| StockVane Quant Rating | D (84) | C (69) |
| Company | ||
| Employees | 4,100 | 65,177 |
| Founded | -- | 2017 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.